Why the study?
Are leptin to insulin and adiponectin to endothelin ratios associated with the extent of coronary atherosclerosis in patients with coronary artery disease?
Are leptin to insulin and adiponectin to endothelin ratios associated with the extent of coronary atherosclerosis in patients with coronary artery disease?
Leptin to insulin and adiponectin to endothelin ratios may serve as sex-specific noninvasive biomarkers for estimating the severity of coronary atherosclerosis.
May support noninvasive early CAD detection via leptin/insulin and adiponectin/endothelin ratios; leaves open validation in larger cohorts.
OBJECTIVE: Noninvasive diagnostics of early stages of coronary artery disease and discrimination between various extents of vascular lesions in patients is an important clinical problem especially considering wide spread use of cholesterol lowering drugs that affect lipid and lipoprotein profiling. The main goal of our study was to evaluate applicability of new combinations of noninvasive biomarkers such as leptin to insulin and adiponectin to endothelin ratios, for detection of early stages of coronary atherosclerosis versus later stages of the disease. PATIENTS AND METHODS: A number of previously validated serum biomarkers were tested in a group of 500 patients with coronary artery disease and examined for their association with severity of coronary lesion according to Gensini score determined by coronary angiography. RESULTS: Lowest extent of coronary lesions was associated with significant increase in apoA-I levels and with significantly increased ratios of adiponectin to endothelin and leptin to insulin. In male but not in female patients, adiponectin to endothelin ratio below 7.0 was associated with Gensini score representing early to high coronary lesions (p = 0.02). In female but not in male patients, leptin to insulin ratio below 3.5 was associated with Gensini score representing early to high coronary lesions (p = 0.013). CONCLUSION: Leptin to insulin and adiponectin to endothelin ratios are novel derived biomarkers useful for noninvasive diagnostics of initial stages of coronary lesions in patients with coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Gumanova et al. (2016) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: